For patients with diabetes, use of agents with demonstrated cardiovascular benefits should be considered in high-risk primary prevention patients, particularly SGLT2 inhibitors and GLP-1 RA [87]. This evidence concerns the gene SLC5A2 and rheumatoid arthritis.